Development
Sarepta Therapeutics, Inc.
SRPT
$16.75
-$0.35-2.05%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 1.68B | 1.73B | 1.86B | 1.88B | 1.99B |
| Total Receivables | 439.71M | 354.26M | 267.16M | 288.08M | 261.60M |
| Inventory | 322.86M | 244.01M | 226.88M | 202.68M | 203.97M |
| Prepaid Expenses | 30.15M | 28.24M | 27.40M | 28.73M | 29.64M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 110.36M | 90.79M | 90.47M | 86.80M | 73.28M |
| Total Current Assets | 2.58B | 2.45B | 2.47B | 2.49B | 2.56B |
|
|
|||||
| Total Current Assets | 2.58B | 2.45B | 2.47B | 2.49B | 2.56B |
| Net Property, Plant & Equipment | 357.11M | 345.82M | 323.60M | 244.88M | 244.99M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 29.62M | 19.50M | 18.02M | 7.20M | 7.58M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 291.99M | 286.04M | 280.66M | 288.33M | 286.62M |
| Total Assets | 3.26B | 3.11B | 3.13B | 3.06B | 3.13B |
|
|
|||||
| Total Accounts Payable | 164.92M | 87.95M | 109.80M | 106.71M | 95.88M |
| Total Accrued Expenses | 200.08M | 202.61M | 219.61M | 253.32M | 335.67M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 123.33M | 17.95M | 16.99M | 17.38M | 15.49M |
| Total Finance Division Other Current Liabilities | 165.33M | 142.23M | 152.26M | 159.47M | 172.57M |
| Total Other Current Liabilities | 165.33M | 142.23M | 152.26M | 159.47M | 172.57M |
| Total Current Liabilities | 653.66M | 450.74M | 498.65M | 536.88M | 619.60M |
|
|
|||||
| Total Current Liabilities | 653.66M | 450.74M | 498.65M | 536.88M | 619.60M |
| Long-Term Debt | 1.13B | 1.24B | 1.24B | 1.23B | 1.54B |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 140.97M | 134.75M | 129.17M | 53.93M | 57.58M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 478.10M | 523.10M | 521.14M | 521.94M | 521.94M |
| Total Liabilities | 2.41B | 2.35B | 2.38B | 2.35B | 2.74B |
|
|
|||||
| Common Stock & APIC | 5.30B | 5.26B | 5.19B | 5.14B | 4.30B |
| Retained Earnings | -4.45B | -4.49B | -4.45B | -4.43B | -3.91B |
| Treasury Stock & Other | 918.00K | -638.00K | -1.06M | -419.00K | -1.66M |
| Total Common Equity | 859.34M | 764.36M | 741.41M | 712.75M | 384.95M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 859.34M | 764.36M | 741.41M | 712.75M | 384.95M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 859.34M | 764.36M | 741.41M | 712.75M | 384.95M |
|
|
|||||